Sarepta Therapeutics, Navistar International, Wal-Mart Stores Trivago
Sarepta released positive study results for a new treatment for Duchenne Muscular Dystrophy
Company
Sarepta Therapeutics Inc
NASDAQ:SRPT
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of both rare and infectious diseases.
45 stories · page 2 of 3
Sarepta Therapeutics Inc, Microsoft Corp, eBay Inc and more
We are seeing what is moving the needle in pre-market deals in New York
Summit Therapeutics to receive US$22mln milestone payment as final patient enrols for DMD trial
Summit hopes the trial will identify utrophin modulation as a potential disease-modifying treatment for all patients suffering Duchenne Muscular Dystrophy
Summit Therapeutics is cashed-up and looking forward to exciting year
The company is well-placed as it looks forward to the continuation of its Phase 2 proof of concept trial for its lead utrophin modulator, ezutromid, and preparation work on its ridinilazole antibiotic
Sarepta sells Priority Review Voucher for US$125mln
A PRV entitles the holder to a priority review of a single New Drug Application or Biologics License Application
Catabasis Pharmaceuticals reports positive pre-clinical data for DMD treatment
Dr H Lee Sweeney, who led the research, said: "There remains a large unmet need in Duchenne for therapies that can treat all affected boys and slow disease progression.
Summit and Sarepta: The key questions answered
We put some of your queries to life sciences research analyst Sheena Berry, of N+1 Singer, who has shed an analytical light on the licensing deal
Structure of Summit deal is beneficial to Sarepta, Wedbush believes
“In our view, this deal structure is beneficial to Sarepta, with a commitment to development only after proof-of-concept data are obtained,” Wedbush said.
Proactive news round-up: Summit Therapeutics, Venn Life, Fox Marble...
A snapshot of today's breaking newswire stories on Proactive
Sarepta licenses DMD treatment from Summit
The pair will collaborate on Summit’s potentially breakthrough treatment for Duchenne muscular dystrophy (DMD)
Close: Stocks slide on hawkish central bank commentary
Stocks turned back after a modestly firmer opening on concerns that global interest rates could head higher sooner than expected
Investments and investor services
FTSE 100 closes just below its all-time high
The FTSE 100 index surpassed its all-time closing high during the day but could not sustain it
Sarepta Therapeutics starts dosing in new DMD trial
Approximately 99 patients aged 7 to 13 years inclusive will be enrolled with a minimum target of 45 patients.
Sarepta Therapeutics surges after reports critic leaves FDA
Shares of beleaguered Sarepta Therapeutics surged by more than one quarter on Wednesday after reports that a key critic of its muscular dystrophy medication left the US Food and Drug Administration, prompting speculation of imminent FDA app
Sarepta surges on new hopes for its DMD drug
The all important body, the FDA, has requested additional data from an ongoing study as it decides whether to approve the drug or not.
Sarepta shares jump as FDA fails to deliver verdict
Sarepta Therapeutics shares shot 21% higher as the beleaguered company won a kind of reprieve when the regulator Food and Drug Administration said it is delaying its review of a key drug made by the firm.
Hope for Sarepta Therapeutics DMD drug despite FDA refusal
All is not lost for Sarepta Therapeutics, as a report suggests the firm could still secure FDA approval for its muscular dystrophy drug previously denied by an advisory panel.
Archive
US stocks gain with oil despite Exxon Mobil rating shocker
US shares nudged higher thanks to solid gains by oil prices. But the energy sector gains come all too late to save US oil titan Exxon Mobil from losing its triple-A credit crown after 60 years
Summit provides renewed hope for sufferers of muscle wasting disease
Shares in Summit Therapeutics rose 4% after the FDA today allowed the company to broaden the scope of its phase II clinical trial of its drug ezutromid to trial sites in the US.
Sarepta plunges as FDA committee rejects DMD drug
While not binding on the FDA, the US regulator normally takes advisory committee advice into consideration when reviewing new drug applications